{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:26:30Z","timestamp":1792783590122,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T00:00:00Z","timestamp":1387152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Telethon \u2014Italy","award":["GGP12108"],"award-info":[{"award-number":["GGP12108"]}]},{"DOI":"10.13039\/501100003407","name":"MIUR","doi-asserted-by":"crossref","award":["2009MBHZPR_002"],"award-info":[{"award-number":["2009MBHZPR_002"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.bbagen.2013.12.018","type":"journal-article","created":{"date-parts":[[2013,12,21]],"date-time":"2013-12-21T05:15:57Z","timestamp":1387602957000},"page":"1214-1224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A thermodynamic assay to test pharmacological chaperones for Fabry disease"],"prefix":"10.1016","volume":"1840","author":[{"given":"Giuseppina","family":"Andreotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Citro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Correra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-6553","authenticated-orcid":false,"given":"Maria Vittoria","family":"Cubellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2013.12.018_bb0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jmb.2005.08.020","article-title":"Loss of protein structure stability as a major causative factor in monogenic disease","volume":"353","author":"Yue","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0010","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2183\/pjab.88.18","article-title":"Pharmacological chaperone therapy for Fabry disease","volume":"88","author":"Ishii","year":"2012","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0020","doi-asserted-by":"crossref","first-page":"e57631","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2013.12.018_bb0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2011.569162","article-title":"Pharmacological chaperone therapy for Gaucher disease: a patent review","volume":"21","author":"Benito","year":"2011","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0030","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0035","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0040","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2013.12.018_bb0045","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/hmg\/dds001","article-title":"Novel pharmacological chaperones that correct phenylketonuria in mice","volume":"21","author":"Santos-Sierra","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1172-5-36","article-title":"Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study","volume":"5","author":"Andreotti","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0070","doi-asserted-by":"crossref","first-page":"28386","DOI":"10.1074\/jbc.M112.351056","article-title":"alpha-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants","volume":"287","author":"Siekierska","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1750-1172-8-111","article-title":"Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones","volume":"8","author":"Cammisa","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl. 7","key":"10.1016\/j.bbagen.2013.12.018_bb0080","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1471-2105-14-S7-S9","article-title":"Identification and analysis of conserved pockets on protein surfaces","volume":"14","author":"Cammisa","year":"2013","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0085","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/FPC.0b013e32830500f4","article-title":"Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone","volume":"18","author":"Shin","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bbagen.2013.12.018_bb0100","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbadis.2009.11.003","article-title":"Functional studies of new GLA gene mutations leading to conformational Fabry disease","volume":"1802","author":"Filoni","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2013.12.018_bb0110","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/humu.9520","article-title":"Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone","volume":"29","author":"Shimotori","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/pro.115","article-title":"Determining protein stability in cell lysates by pulse proteolysis and Western blotting","volume":"18","author":"Kim","year":"2009","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0130","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1399-0004.2011.01689.x","article-title":"Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene","volume":"81","author":"Ferri","year":"2011","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-6-66","article-title":"Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests","volume":"6","author":"Andreotti","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0140","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbagen.2013.12.018_bb0145","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0003-9861(80)90281-7","article-title":"A comparison of the effectiveness of protein denaturants for beta-lactoglobulin and ribonuclease","volume":"199","author":"Pace","year":"1980","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0150","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The molecular basis of pharmacological chaperoning in human alpha-galactosidase","volume":"18","author":"Guce","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"Shabbeer","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0160","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.bbagen.2013.12.018_bb0165","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF03401993","article-title":"Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease","volume":"5","author":"Topaloglu","year":"1999","journal-title":"Mol. Med."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s100380170088","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype","volume":"46","author":"Ashley","year":"2001","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0175","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects","volume":"109","author":"Giugliani","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0185","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbagen.2013.12.018_bb0190","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416513005461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416513005461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T03:22:58Z","timestamp":1564975378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416513005461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0304416513005461"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2013.12.018","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A thermodynamic assay to test pharmacological chaperones for Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2013.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}